Letrozole in Paediatric Females for Peripheral Precocious Puberty: A Systematic Review of Efficacy and Safety
Clicks: 2
ID: 328304
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #383 of 383 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 383 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
CONTEXT: Letrozole, a third-generation aromatase inhibitor, has been increasingly investigated as an off-label treatment to improve growth outcomes in paediatric boys, whereas its use in girls has remained limited because of concerns regarding safety and efficacy, given the critical role of oestrogens in female physiology. This gender gap has delayed research on letrozole in girls. OBJECTIVE: To systematically evaluate the clinical efficacy, growth outcomes, and safety profile of letrozole in girls with peripheral precocious puberty (PPP). EVIDENCE ACQUISITION: PubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to May 2026, following PRISMA 2020 guidelines (PROSPERO: CRD420261423918). Eligible studies evaluated letrozole monotherapy in girls aged ≤18 years. Risk of bias was assessed using JBI checklists and Murad tool. Data were synthesised narratively according to the SWiM guideline. EVIDENCE SYNTHESIS: Twenty-two observational studies encompassing 151 female patients were included. Twenty-one studies evaluated letrozole for PPP, predominantly McCune-Albright syndrome, where treatment effectively slowed pubertal progression, reduced bone age advancement, and improved predicted adult height. One exploratory study evaluated girls with short stature without pubertal disorders. Transition to central precocious puberty occurred during follow-up in 41.3% of patients. Safety was favourable (adverse events: 3.3%), with no clinically significant hyperandrogenism or hepatotoxicity. CONCLUSIONS: Letrozole demonstrates meaningful clinical benefits in girls with PPP, particularly regarding pubertal control and predicted adult height, accompanied by a favourable safety profile. Well-designed prospective studies are needed to establish optimal dosing, long-term safety, and final adult height outcomes in the female paediatric population.
| Reference Key |
openalex_W7212081128
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Carlotta Tartarini, Eugenio Trinati, Gaia Varriale, Martina Sica, Renato Vaiasuso, Alessandro Barbato, Alessio Rossi, Stefano Stagi |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag372
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.